Jari E Karppinen, Laura Suojanen, Sini Heinonen, Sanna Kaye, Birgitta W van der Kolk, James W White, Janne Orava, Seung Hyuk T Lee, Eugené Dillon, Maheswary Muniandy, Aila Rissanen, Carel W le Roux, Neil Docherty, Päivi Pajukanta, Kirsi A Virtanen, Kirsi H Pietiläinen
{"title":"Effects of Whole-Body Cryotherapy Combined With Conventional Obesity Management Versus Obesity Management Alone: A Clinical Trial.","authors":"Jari E Karppinen, Laura Suojanen, Sini Heinonen, Sanna Kaye, Birgitta W van der Kolk, James W White, Janne Orava, Seung Hyuk T Lee, Eugené Dillon, Maheswary Muniandy, Aila Rissanen, Carel W le Roux, Neil Docherty, Päivi Pajukanta, Kirsi A Virtanen, Kirsi H Pietiläinen","doi":"10.1002/oby.70019","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether whole-body cryotherapy (WBC) enhances weight loss, brown adipose tissue (BAT) activation, and metabolic outcomes during obesity management.</p><p><strong>Methods: </strong>Nineteen adults with obesity were assigned to a 12-month lifestyle-based obesity management intervention with 28 WBC sessions (-110°C, 3-4 min, ~2 × week) over the first 5 months (CRYO, n = 10) or the intervention without WBC (CON, n = 9). The primary outcome was weight loss (5 and 12 months). Secondary outcomes included BAT glucose uptake and whole-body energy expenditure during cold stimulation (5 months), clinical parameters, subcutaneous adipose tissue transcriptomics, and skeletal muscle proteomics (5 and 12 months).</p><p><strong>Results: </strong>Weight loss in the CRYO group was 11.9% at 5 months and 9.9% at 12 months, compared to 11.5% and 8.0% in the CON group (p ≥ 0.54 for between-group differences). No significant between-group differences appeared in BAT glucose uptake, energy expenditure, adipose tissue transcriptomics, or skeletal muscle proteomics changes. However, at 5 months, the CRYO group showed greater reductions in fasting glucose (0.41 mmol/L, p = 0.026) and LDL cholesterol (0.44 mmol/L, p = 0.034).</p><p><strong>Conclusions: </strong>WBC did not significantly enhance weight loss, activate BAT, or alter most metabolic responses during conventional obesity management. Further research is needed to confirm whether WBC benefits glucose and cholesterol metabolism.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT01312090.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity (Silver Spring, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/oby.70019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate whether whole-body cryotherapy (WBC) enhances weight loss, brown adipose tissue (BAT) activation, and metabolic outcomes during obesity management.
Methods: Nineteen adults with obesity were assigned to a 12-month lifestyle-based obesity management intervention with 28 WBC sessions (-110°C, 3-4 min, ~2 × week) over the first 5 months (CRYO, n = 10) or the intervention without WBC (CON, n = 9). The primary outcome was weight loss (5 and 12 months). Secondary outcomes included BAT glucose uptake and whole-body energy expenditure during cold stimulation (5 months), clinical parameters, subcutaneous adipose tissue transcriptomics, and skeletal muscle proteomics (5 and 12 months).
Results: Weight loss in the CRYO group was 11.9% at 5 months and 9.9% at 12 months, compared to 11.5% and 8.0% in the CON group (p ≥ 0.54 for between-group differences). No significant between-group differences appeared in BAT glucose uptake, energy expenditure, adipose tissue transcriptomics, or skeletal muscle proteomics changes. However, at 5 months, the CRYO group showed greater reductions in fasting glucose (0.41 mmol/L, p = 0.026) and LDL cholesterol (0.44 mmol/L, p = 0.034).
Conclusions: WBC did not significantly enhance weight loss, activate BAT, or alter most metabolic responses during conventional obesity management. Further research is needed to confirm whether WBC benefits glucose and cholesterol metabolism.
目的：探讨全身冷冻疗法（WBC）是否能促进肥胖治疗期间的体重减轻、棕色脂肪组织（BAT）激活和代谢结果。方法：19名肥胖成人被分配到为期12个月的基于生活方式的肥胖管理干预组，前5个月有28次白细胞计数（-110°C， 3-4分钟，~2周）（CRYO, n = 10）或没有白细胞计数的干预组（CON, n = 9）。主要结局是体重减轻（5个月和12个月）。次要结局包括冷刺激期间（5个月）BAT葡萄糖摄取和全身能量消耗、临床参数、皮下脂肪组织转录组学和骨骼肌蛋白质组学（5个月和12个月）。结果：CRYO组5个月和12个月体重分别减轻11.9%和9.9%，CON组分别为11.5%和8.0%（组间差异p≥0.54）。在BAT葡萄糖摄取、能量消耗、脂肪组织转录组学或骨骼肌蛋白质组学变化方面，组间无显著差异。然而，在5个月时，CRYO组空腹血糖（0.41 mmol/L, p = 0.026）和低密度脂蛋白胆固醇（0.44 mmol/L, p = 0.034）的降低幅度更大。结论：在传统的肥胖管理过程中，WBC并没有显著促进体重减轻、激活BAT或改变大多数代谢反应。白细胞是否有利于葡萄糖和胆固醇代谢还需要进一步的研究来证实。试验注册：ClinicalTrials.gov: NCT01312090。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
